

The 2026 Bundibugyo Ebola Outbreak

in the Democratic Republic of the Congo and Uganda

September 2026



Abstract

The 2026 outbreak of Ebola disease caused by Bundibugyo ebolavirus in the Democratic Republic of the Congo and Uganda represents a major test of global filovirus preparedness. The event was confirmed in May 2026 after clusters of severe disease and health-care-worker deaths in Ituri Province, DRC, with subsequent cross-border involvement of Uganda. As of mid-July 2026, the outbreak had expanded across multiple eastern DRC provinces and remained epidemiologically linked to limited transmission in Uganda. The response is complicated by delayed recognition, community deaths, local beliefs and vaccine skepticism, insecurity, population mobility, health-system constraints, and the absence of licensed Bundibugyo-specific vaccines, therapeutics, or widely deployed rapid diagnostics at the outset.

This white paper synthesizes the virologic, epidemiologic, clinical, operational, and regulatory dimensions of the outbreak, with particular emphasis on diagnostic strategy, pseudovirus neutralization assays, vaccine development, manufacturing readiness, and pathways for emergency evidence generation.

Three principal vaccine platforms are being accelerated: a recombinant vesicular stomatitis virus vector expressing Bundibugyo glycoprotein, a ChAdOx1 adenoviral-vector candidate, and an mRNA-based candidate. The paper compares platform rationale, manufacturing readiness, clinical-evaluation options, and plausible regulatory pathways, including outbreak efficacy studies, immunobridging, animal-model evidence, emergency authorization, and post-authorization effectiveness assessment.

In conclusion, effective Bundibugyo preparedness requires not only candidate vaccines, but an integrated system of surveillance, constant development of updated diagnostic tools, clinical research, manufacturing, access commitments, regulatory convergence, and community trust.

About Lighthouse BioSolutions: Lighthouse BioSolutions provides scientific and strategic consulting for biologics development, including translational strategy, vaccine development, immune monitoring, assay development, and regulatory planning. This paper translates the Bundibugyo outbreak into practical considerations for organizations developing or evaluating filovirus diagnostics, vaccines, and clinical programs.

Publication note: This white paper reflects information available as of its stated publication date. Because outbreak conditions and medical-countermeasure development can change rapidly, readers should consult the latest WHO, Africa CDC, and national public-health updates before relying on epidemiologic figures or development-status statements. Lighthouse BioSolutions will identify substantive revisions by date and version number.

Recommended citation: *Lighthouse BioSolutions. The 2026 Bundibugyo Ebola Outbreak in the Democratic Republic of the Congo and Uganda. White paper, August 2026. Version 1.0.*

Keywords: Bundibugyo ebolavirus; Ebola disease; Democratic Republic of the Congo; Uganda; rVSV; ChAdOx1; mRNA vaccines; CEPI; IAVI; Oxford Vaccine Group; Moderna; emergency use authorization; immunobridging; Animal Rule; outbreak clinical trials.



Table of Contents

Abstract	1
Table of Contents	3
1. Executive Summary	4
2. Outbreak Background and Epidemiologic Context	4
3. Virology and Disease Characteristics	5
3.1 Molecular Biology and Pathogenesis	6
3.2 Comparison with Previous Bundibugyo Outbreaks	7
4. Diagnostic Approaches and Biological Mechanisms	8
5. Pseudovirus neutralization assays	10
6. Public-Health Response Priorities	14
7. Historical Perspective on Ebola Vaccines	16
8. Vaccine Development Landscape for Bundibugyo Ebolavirus	17
8.1 Recombinant Vesicular Stomatitis Virus Vector	17
8.2 Adenoviral-Vector Platforms	18
8.3 mRNA Vaccine Platforms	18
9. Candidate Platforms, Sponsors, Funders, and Development Considerations	19
9.1 Manufacturing, Access, and Stockpile Strategy	20
10. Regulatory Strategy	21
11. Operational Considerations for Vaccine Trials	22
12. Strategic Implications for Filovirus Preparedness	23
13. Conclusions	24
14. References	24



1. Executive Summary

The 2026 Ebola outbreak affecting the Democratic Republic of the Congo and Uganda is caused by Bundibugyo ebolavirus, a filovirus species for which no licensed vaccine, specific therapeutic, or broadly deployed rapid diagnostic had been available at the outset of the event. The outbreak was confirmed in Ituri Province, DRC, in mid-May 2026 after clusters of high-mortality illness, including deaths among health workers, and subsequently involved Uganda through imported and limited local transmission. By mid-July 2026, public reporting indicated that the outbreak had become one of the largest Ebola events on record, with intense transmission in eastern DRC and a substantially more contained situation in Uganda.

The scientific and operational challenge is distinctive: licensed Ebola vaccines such as rVSV-ZEBOV target Zaire ebolavirus and cannot be assumed to protect against Bundibugyo ebolavirus. The current response therefore depends on classical outbreak-control measures, optimized supportive care, clinical evaluation of investigational therapeutics, accelerated vaccine development, and rigorous ethical research during an emergency. Vaccine efforts currently emphasize three main approaches: a single-dose recombinant vesicular stomatitis virus vector expressing Bundibugyo glycoprotein, adenoviral-vector approaches including ChAdOx1 or related chimpanzee adenovirus platforms, and mRNA vaccines encoding Bundibugyo antigens. These platforms differ in manufacturing speed, prior regulatory experience, durability of evidence, cold-chain demands, and feasibility for ring vaccination or targeted prophylaxis.

2. Outbreak Background and Epidemiologic Context

Bundibugyo virus disease was first recognized as a distinct Ebola disease syndrome after earlier outbreaks in Uganda and the DRC. The 2026 event was initially detected as a high-mortality syndrome in northeastern DRC, with laboratory confirmation by national reference testing. The outbreak rapidly expanded across multiple DRC provinces, especially Ituri and North Kivu, and included cases in Uganda, largely linked to movement from DRC. The context combines biologic, geographic, and social risk factors: delayed diagnosis, community deaths, health-care-associated transmission, insecurity, mobile populations, cross-border commerce, misinformation, and limits in laboratory and clinical capacity.

Available situation reports describe several high-risk features. First, a large proportion of new cases have not been identified among known contacts, implying missed transmission chains. Second, many deaths have occurred in communities rather than in treatment centers, indicating delays in detection and referral. Third, the outbreak is occurring amid active conflicts and attacks on health infrastructure, complicating surveillance, isolation, safe burial, contact tracing, and community engagement. Fourth, Uganda's cases illustrate the regional risk created by frequent movement between affected DRC provinces and major urban centers.

Figure 1. Conceptual outbreak pathway




Figure 1. Conceptual outbreak pathway. Delayed detection in a conflict-affected, mobile population can allow unrecognized community transmission, health-care-associated amplification, cross-border seeding, and expansion into urban or transit-linked settings.

3. Virology and Disease Characteristics

Bundibugyo ebolavirus is an orthoebolavirus within the family Filoviridae. Like other pathogenic ebolaviruses, it causes an acute febrile illness that can progress to gastrointestinal symptoms, vascular leakage, hemorrhagic manifestations, shock,

multiorgan dysfunction, and death. Transmission occurs through direct contact with blood or bodily fluids of symptomatic patients, contaminated materials, unsafe health-care practices, and exposure during funerary care. The incubation period is typically compatible with the broader Ebola disease range, and the operational control strategy relies on rapid case detection, isolation, infection prevention and control, contact tracing, safe and dignified burial, and risk communication.

Bundibugyo ebolavirus is genetically and antigenically distinct from Zaire ebolavirus, Sudan ebolavirus, Tai Forest ebolavirus, and other related filoviruses. This distinction is central to vaccine strategy because the major licensed Ebola vaccine experience is species-specific for Zaire ebolavirus. Cross-protection cannot be assumed without supporting evidence, and an outbreak of Bundibugyo disease therefore exposes a critical gap in the global filovirus medical-countermeasure portfolio.

Characteristic	Operational implication
Direct-contact transmission through infectious bodily fluids	Prioritizes early isolation, personal protective equipment, safe burial, and exposure-based contact tracing.
Species-level antigenic distinction from Zaire ebolavirus	Existing Zaire-targeted vaccine evidence cannot be assumed to confer protection against Bundibugyo disease.
High case-fatality potential without early supportive care	Requires rapid referral, aggressive supportive care, and strengthened treatment-center capacity.
Rare prior outbreak history	Limits clinical evidence and creates dependence on platform inference, animal data, and emergency research designs.

Table 1. Virologic and operational features of Bundibugyo virus disease relevant to outbreak response and vaccine strategy.

3.1 Molecular Biology and Pathogenesis

Bundibugyo ebolavirus is an enveloped, non-segmented, negative-sense RNA virus of the Filoviridae family. Its genome encodes the canonical filovirus proteins NP, VP35, VP40, GP, VP30, VP24, and L. The viral glycoprotein mediates attachment and entry, while the ribonucleoprotein complex and polymerase support genome transcription and replication

in the cytoplasm. As with other ebolaviruses, disease reflects both direct viral replication and dysregulated host responses, including innate immune antagonism, endothelial activation, cytokine-mediated inflammation, coagulation abnormalities, and impaired barrier function.

The 2026 outbreak is biologically important because available genomic analyses indicate that circulating viruses are Bundibugyo ebolavirus but represent a new variant linked to the current DRC-Uganda transmission event. This matters operationally: sequence divergence can affect primer and probe binding for molecular diagnostics, antigen recognition by rapid tests, and the antigenic fit of vaccines or antibody-based therapeutics. Genome sequencing therefore serves both an epidemiologic purpose, by reconstructing transmission chains, and a countermeasure purpose, by confirming whether assays, vaccines, and therapeutics remain well matched to the circulating virus.

At the cellular level, Bundibugyo virus disease is expected to follow the broader ebolavirus pathogenesis pattern. Early replication in monocytes, macrophages, dendritic cells, and other permissive cells can impair antigen presentation and interferon responses. Viral proteins such as VP35 and VP24 are implicated in blocking antiviral signaling pathways in related ebolaviruses, enabling high viral loads before adaptive immunity is fully mobilized. The glycoprotein contributes to cell entry and may also contribute to vascular and inflammatory pathology. These mechanisms explain why early diagnosis, isolation, supportive care, and infection prevention remain central even when vaccines and therapeutics are under development.

3.2 Comparison with Previous Bundibugyo Outbreaks

Bundibugyo virus disease has been documented in three recognized outbreak periods: the first recognized outbreak in Bundibugyo District, Uganda, in 2007–2008; a second outbreak in the Isiro region of the Democratic Republic of the Congo in 2012; and the current 2026 outbreak in the Democratic Republic of the Congo and Uganda. Earlier outbreaks were smaller and more geographically limited, with reported case-fatality estimates generally in the range of roughly one-third to one-half depending on case classification. The 2026 event differs by scale, cross-border spread, operational complexity, and the degree to which genomic, diagnostic, vaccine, and therapeutic questions are being addressed in real time.

Outbreak period	Biological and epidemiologic interpretation	Response implication
2007–2008 Uganda	First recognized Bundibugyo virus outbreak; established the virus as a distinct cause of Ebola disease in humans.	Created the need for species-specific diagnostics and countermeasure development beyond Zaire ebolavirus.
2012 DRC	Genomic analysis later suggested earlier circulation, multiple lineages, or multiple spillover events rather than a single simple introduction.	Demonstrated the value of genomic surveillance, specimen archiving, and integrated field epidemiology.
2026 DRC- Uganda	A larger, cross-border event involving a newly described Bundibugyo variant and complex transmission in conflict-affected settings.	Requires decentralized diagnostics, sequencing, clinical research, vaccine evaluation, and cross-border coordination.

Table 5. Comparison of recognized Bundibugyo virus disease outbreaks and implications for the 2026 response.

4. Diagnostic Approaches and Biological Mechanisms

Diagnostic strategy for Bundibugyo virus disease depends on the biology of viral replication, antigen expression, and host immune kinetics. During acute infection, viral RNA and viral proteins are present in blood and other clinical specimens, especially after symptom onset and during high-viremia illness. Molecular assays detect viral RNA and are therefore best suited for confirming acute infection. Antigen assays detect viral proteins and can support decentralized triage when sufficiently sensitive and specific. Serology detects host antibodies and is most useful for retrospective investigation, survivor studies, and epidemiologic reconstruction rather than early case confirmation.

Real-time reverse-transcription PCR remains the diagnostic gold standard. The biological mechanism is sequence recognition: viral RNA is extracted, converted into complementary DNA, and amplified using primers and probes designed to bind conserved or species-specific genomic regions. Fluorescent signal accumulation indicates amplification and supports qualitative detection. Broad filovirus screening assays can identify Ebola- or Marburgvirus RNA, while typing assays and Bundibugyo-specific assays distinguish Bundibugyo virus from Zaire, Sudan, Taï Forest, or other filoviruses. Because primer or

probe mismatches can reduce sensitivity, current-outbreak sequencing is essential to verify assay performance against the circulating variant.

Antigen-detection rapid diagnostic tests use antibodies immobilized on a lateral-flow or related immunoassay platform to capture viral proteins such as nucleoprotein, VP40, or glycoprotein. A positive result depends on sufficient antigen concentration and antibody recognition of the relevant epitope. These tests can be valuable for rapid triage, safe burial decisions, and decentralized screening, but performance can vary by viral species, viral load, specimen type, and antigenic divergence. In the current Bundibugyo outbreak, Africa CDC concluded that no antigen rapid diagnostic test met the target product profile specifications for recommendation at the time of its May 2026 review, making laboratory-based RT-PCR the central confirmatory approach.

Serologic assays detect the host immune response, typically IgM as a marker of recent infection and IgG as a marker of later or past exposure. The mechanism is antigen-antibody binding: recombinant viral proteins or infected-cell antigens capture patient antibodies, which are then detected by labeled secondary reagents. Serology is limited during the earliest symptomatic period because antibodies may not yet be present, and interpretation can be complicated by cross-reactivity among ebolavirus species. Nevertheless, serology can clarify missed transmission, survivor immune responses, and population-level exposure after an outbreak.

Diagnostic approach	Biological target	Mechanism	Use in prior and current outbreaks
Real-time RT-PCR	Viral RNA	Reverse transcription followed by sequence-specific amplification and fluorescent probe detection.	Primary confirmatory method in prior Ebola outbreaks and the central recommended approach for the 2026 Bundibugyo response.
Antigen rapid diagnostic test	Viral proteins such as NP, VP40, or GP	Antibody capture of viral antigen on a lateral-flow or immunoassay membrane.	Useful in some Zaire ebolavirus contexts, but not recommended for 2026 Bundibugyo deployment without adequate validation.
Serology	Host IgM or IgG antibodies	Binding of patient antibodies to viral antigens, detected by labeled secondary reagents.	Best suited for retrospective epidemiology, survivor studies, and exposure assessment rather than early case confirmation.
Genomic sequencing	Whole or partial viral genome	Determines nucleotide sequence to classify variants, infer transmission, and assess assay or antigen match.	Retrospectively clarified 2012 outbreak dynamics and is central to tracking the 2026 variant and transmission chains.

Table 6. Diagnostic methods for Bundibugyo virus disease and their biological mechanisms.

5. Pseudovirus neutralization assays

Pseudovirus neutralization assays (PVNAs) are essential tools for measuring Ebola virus (EBOV)–specific neutralizing antibodies in both immunogenicity studies (e.g., vaccine trials) and seroprevalence studies (e.g., outbreak investigations). They provide a safe, scalable, and biologically relevant alternative to live-virus neutralization assays, which require BSL-4 containment.

Why this matters for development programs: The choice of neutralization assay affects comparability across vaccine candidates, confidence in immunobridging, laboratory transferability, and the credibility of evidence submitted to regulators. Sponsors should

therefore select the assay platform, reference standards, acceptance criteria, and cross-laboratory validation strategy early enough to support both clinical development and emergency evidence generation.

Core Concept

PVNAs use non-replicating viral particles (typically lentiviral or vesicular stomatitis virus [VSV] backbones) engineered to express the Ebola glycoprotein (GP) on their surface. Because GP is the primary target of neutralizing antibodies, these pseudoviruses mimic EBOV entry into host cells without the biosafety risks of live EBOV. Neutralization is quantified by measuring the reduction in reporter signal (fluorescence, luminescence, or PCR readout) after incubation with serum samples.

This allows BSL-2 laboratories to perform neutralization testing safely and at scale.

Assay Design and Workflow

1. Pseudovirus Generation

- Backbone: Lentiviral vectors or VSV-based pseudotypes.
- Surface protein: EBOV GP (commonly Zaire ebolavirus GP).
- Reporter gene: GFP, luciferase, or other fluorescent/enzymatic markers for quantification.
- These pseudoviruses are entry-competent but replication-deficient, ensuring safety.

2. Neutralization Step

Serum samples (from vaccine recipients, survivors, or population surveys) are serially diluted. Diluted sera are then incubated with pseudovirus particles, allowing neutralizing antibodies to bind GP, therefore preventing pseudovirus entry into target cells.

3. Infection and Readout

The PVNA-serum mixtures are added to permissive cell lines (e.g., HEK293T). After incubation, reporter expression is then quantified:

- Fluorescence reduction neutralization tests (FRNT) for VSV-based pseudotypes.
- Luminescence assays for lentiviral pseudotypes.

- Neutralization titers (e.g., IC50) are calculated based on signal reduction.

Applications in Ebola Immunogenicity Studies

1. Vaccine Evaluation

PVNAs are widely used to measure neutralizing antibody responses in:

- EBOV vaccine trials (e.g., rVSV-ZEBOV).
- Monoclonal antibody therapeutic development.

Of note, while neutralizing antibody titers are key immunogenicity endpoints, historically, heterogeneous assay platforms have made cross-study comparisons difficult.

PVNAs provide:

- Standardization potential across labs.
- High-throughput capability for large clinical trials.
- Correlation with live-virus neutralization, though correlation strength varies by platform.
 - VSV-based pseudotype assays have showed strong correlation with BSL-4 live EBOV assays. It should be noted, however, that HIV-1-based pseudotypes show somewhat lower correlation.

2. Bridging Assays

PVNAs serve as bridging assays between the high-biosafety live EBOV neutralization tests, and the more scalable, GCLP-compatible platforms. This is especially important in outbreak-prone regions where BSL-4 access is limited.

Applications in Seroprevalence Studies During Outbreaks

1. Population-Level Immunity Assessment

During Ebola outbreaks, PVNAs allow rapid assessment of:

- Exposure history in affected communities.
- Asymptomatic or mild infections.
- Durability of antibody responses in survivors.

Because they can be performed in BSL-2 settings, PVNAs dramatically expand testing capacity in resource-limited regions.

2. Outbreak Response

PVNAs support:

- Identification of individuals with high neutralizing titers (potential convalescent plasma donors).
- Evaluation of community immunity to guide public health interventions.
- Monitoring of antibody waning over time.

Variants of PVNAs Used in Ebola Research

1. Lentiviral Pseudoparticle Neutralization Test (PPNT)

This platform uses lentiviral vectors pseudotyped with EBOV GP. It is suitable for BSL-2 labs and provides sensitive detection of neutralizing antibodies.

2. VSV-Based Fluorescence Reduction Neutralization Test (FRNT)

This assay platform, which uses replication-deficient VSV particles expressing EBOV GP, has demonstrated a strong correlation with BSL-4 live-virus assays.

3. Replication-Competent VSV Hybrid Virus with qPCR Readout

This platform allows micro-neutralization assays with quantitative PCR endpoints and is extremely useful for high-throughput vaccine studies.

4. Biologically Contained EBOVΔVP30 Assay

Although not a pseudovirus, this BSL-2-compatible system is often compared with pseudovirus assays. By relying on an EBOV lacking VP30 gene (requires VP30-expressing cells), it provides multi-cycle replication under BSL-2 conditions, and has showed stronger correlation with live EBOV neutralization than pseudotyped platforms.

PVNAs' Strengths and Limitations

Strengths	Limitations
• BSL-2 compatible → scalable and accessible. • Safe → no handling of replication-competent EBOV. • High throughput → suitable for large vaccine trials and outbreak serosurveys. • Biologically relevant → GP-mediated entry mimics authentic EBOV infection. • Correlates with live-virus neutralization, enabling surrogate endpoints.	• Platform heterogeneity complicates cross-study comparisons. • Single-cycle entry assays may not fully capture multi-cycle replication dynamics. • Reporter-based readouts can vary in sensitivity across platforms. • Lower correlation for some pseudovirus backbones (e.g., HIV-1).

Summary

Pseudovirus neutralization assays are indispensable for Ebola immunogenicity and seroprevalence research. They provide a safe, standardized, and scalable method to quantify neutralizing antibodies, enabling both vaccine evaluation and outbreak response in settings where BSL-4 facilities are unavailable. Their strong correlation with live-virus assays—especially for VSV-based platforms—makes them reliable surrogate endpoints for protective immunity.

6. Public-Health Response Priorities

The immediate response priorities are to interrupt transmission while generating evidence for medical countermeasures. Core measures include case investigation, active surveillance, contact listing and follow-up, rapid laboratory confirmation, safe clinical care, infection prevention and control in health facilities, safe and dignified burials, border and travel-related preparedness, community-led communication, and protection of essential health services. The operational objective is not only to reduce case fatality but also to

shorten the time between symptom onset, testing, isolation, and initiation of supportive care.

Clinical management emphasizes aggressive supportive care: fluid and electrolyte management, hemodynamic monitoring, treatment of coinfections, nutritional support, pain control, management of bleeding and organ dysfunction, and protection of health workers. In parallel, WHO-convened expert groups have prioritized investigational therapeutics for evaluation in clinical trials, including monoclonal antibody candidates and antivirals. Therapeutic studies are scientifically important because improved survival may reduce community fear, increase early presentation, and strengthen trust in treatment centers.

Figure 2. Response architecture




Figure 2. Response architecture. Surveillance, diagnostics, care, infection prevention and control, safe burial, and community engagement operate as an integrated response system, with research embedded to evaluate countermeasures without disrupting operations.

7. Historical Perspective on Ebola Vaccines

The modern Ebola vaccine field was shaped by the 2014–2016 West Africa epidemic and subsequent DRC outbreaks. The most important precedent is the development and deployment of rVSV-ZEBOV, a recombinant vesicular stomatitis virus vector expressing the Zaire ebolavirus glycoprotein. This vaccine demonstrated effectiveness in ring-vaccination studies and became a central tool in Zaire ebolavirus outbreak response. Additional platforms, including adenoviral vectors and heterologous prime-boost regimens, have also contributed to the evidence base for filovirus vaccination.

An historical lesson sums up the current challenges: vaccine preparedness must be species-specific and outbreak ready. Zaire ebolavirus vaccines were able to move rapidly because candidate products, clinical protocols, manufacturing processes, regulatory packages, and ethical frameworks had been advanced before major outbreaks. By contrast, Bundibugyo ebolavirus has received less sustained investment, leaving the 2026 response dependent on accelerated development of candidates that are scientifically promising but not yet licensed.

Period	Key lesson for Bundibugyo preparedness
1976 onward: recognition of multiple ebolavirus species	Medical countermeasures must account for species-specific antigenic and epidemiologic differences.
2007–2008 and 2012: prior Bundibugyo outbreaks	Rare outbreaks can still produce severe disease and high mortality, but sporadic incidence weakens commercial incentives.
2014–2016 West Africa epidemic	Late-stage vaccine development and ring-vaccination designs can generate actionable evidence during emergencies.
2018–2020 DRC Zaire ebolavirus outbreaks	Stockpiles, regulatory readiness, and community trust are as important as biological efficacy.
2026 Bundibugyo outbreak	Preparedness gaps remain for non-Zaire ebolaviruses, especially Bundibugyo and Sudan viruses.

Table 2. Historical milestones shaping current Bundibugyo vaccine-development strategy.

8. Vaccine Development Landscape for Bundibugyo Ebolavirus

CEPI has fast-tracked three candidate vaccines against Bundibugyo ebolavirus under its emergency response framework. The decision reflects the absence of any licensed vaccine against Bundibugyo virus and the urgent need to establish a clinical-stage candidate that could be deployed under emergency use authorization during the ongoing outbreak. CEPI stated that the 100 Days Mission framework would guide its acceleration approach, with the aim of generating safety and immunogenicity data as rapidly as possible. To support this initiative, Africa CDC and WHO have coordinated a continental strategy to contain the Bundibugyo ebolavirus outbreak. The joint continental response plan coordinates surveillance, response capacity, and preparedness activities across African Union member states. The vaccine-development response focuses on translating prior filovirus platform experience to Bundibugyo ebolavirus. Candidate selection is driven by four criteria: biological plausibility of antigen design, platform-specific speed and manufacturability, prior human safety experience, and ability to support emergency clinical evaluation. WHO advisory groups have recommended that candidate vaccines and therapeutics be used within clinical trials wherever feasible, because the outbreak presents both urgent need and a rare opportunity to generate interpretable evidence.

In addition to the three fast-tracked candidates, CEPI also announced, on August 27, 2026, having committed up to \$16.5 million to push the Egyptian drugmaker Minapharm's Bundibugyo vaccine candidate into the clinic. Minapharm is developing a vaccine candidate based on the modified vaccinia Ankara platform. A similar technology has provided long-term immunity against Zaire ebolavirus in earlier studies. CEPI funding positions Minapharm to take its Bundibugyo vaccine candidate through preclinical tests and into an early-stage safety and immunogenicity human trial.

Beyond this Vaccinia Ankara candidate, the three CEPI-fast-tracked vaccine candidates are described below.

8.1 Recombinant Vesicular Stomatitis Virus Vector

The rVSV platform is the most directly validated Ebola vaccine platform because it underlies the licensed Zaire ebolavirus vaccine. For Bundibugyo, the concept is to engineer a replication-competent or attenuated rVSV vector to express Bundibugyo glycoprotein, thereby inducing humoral and cellular immune responses against the relevant species.

IAIV is major sponsor for this candidate, as it has extensive rVSV filovirus platform experience and related programs for Sudan virus. The strategic advantage is platform precedent: single-dose administration, prior outbreak-use experience, and a regulatory analogy to rVSV-ZEBOV. The key uncertainties for this approach relate to the speed of candidate manufacturing, clinical readiness, reactogenicity profile, correlates of protection, and whether immune bridging can support accelerated review.

8.2 Adenoviral-Vector Platforms

Adenoviral vectors provide an alternative approach with substantial human experience from Ebola, COVID-19, and other vaccine programs. The University of Oxford is advancing a ChAdOx1-based Bundibugyo candidate. ChAdOx1 is a non-replicating chimpanzee adenovirus vector that can be rapidly adapted to encode a target antigen. Related chimpanzee adenovirus platforms are also being used in Sudan ebolavirus vaccine development, including Sabin Vaccine Institute's cAd3 program, which provides relevant platform experience even though the antigen target differs. Adenoviral vectors may be attractive for scalable manufacturing and known clinical operations, but they may require careful evaluation of dose, durability, pre-existing vector immunity, safety in special populations, and protection against severe disease.

8.3 mRNA Vaccine Platforms

mRNA vaccines offer the fastest antigen-to-clinic development pathway when sequence, formulation, and manufacturing capacity are available. Moderna is developing an mRNA vaccine candidate against Bundibugyo ebolavirus. The platform's advantages include rapid design, modular manufacturing, and the ability to encode stabilized or optimized glycoprotein antigens. Important limitations include cold-chain complexity, limited filovirus efficacy precedent relative to rVSV-ZEBOV, uncertainty about the immune response needed for rapid post-exposure or ring-vaccination protection, and the need for safety and immunogenicity data in outbreak-relevant populations.

9. Candidate Platforms, Sponsors, Funders, and Development Considerations

Platform	Representative sponsor/developer	Funding and partners	Development status and readiness	Regulatory considerations
rVSV-Bundibugyo glycoprotein	IAVI, with candidate origins in UTMB and supporting prior research from NIAID-linked investigators	CEPI early-development award; additional support from the Government of the Netherlands; CDMO transfer for GMP manufacturing	Strong preclinical rationale and nonhuman-primate protection data; not yet evaluated in humans; expected to require manufacturing and clinical-readiness work before field trials	Most direct analogy to licensed rVSV-ZEBOV; potential single-dose ring-vaccination use; may rely on outbreak efficacy data, immunobridging, and animal-model evidence
ChAdOx1 BDBV	University of Oxford/Oxford Vaccine Group and Pandemic Sciences Institute; manufacturing by Serum Institute of India	CEPI program support; SII manufacturing and stockpiling; planned partnerships with Uganda-based research units	First-in-human Phase I trial launched in Oxford in July 2026 in 50 healthy adults; approximately 620,000 doses reportedly stockpiled and 4,000 investigational doses supplied for trial use	Fastest candidate to enter human testing; requires safety, immunogenicity, and field efficacy or bridging evidence for emergency authorization or licensure

Platform	Representative sponsor/developer	Funding and partners	Development status and readiness	Regulatory considerations
mRNA BDBV vaccine	Moderna	CEPI commitment of up to approximately US\$50 million for preclinical work, Phase I testing, manufacturing readiness, and potential progression to later-stage trials	Rapid design and manufacturing potential; early-stage development; dosing strategy and durability yet to be defined	May support rapid antigen updates and scalable development but lacks the filovirus efficacy precedent of rVSV; regulatory package will require robust safety, immunogenicity, and bridging data

Table 3. Bundibugyo vaccine-development portfolio: platforms, sponsors, funding, readiness, and regulatory implications.

9.1 Manufacturing, Access, and Stockpile Strategy

Manufacturing strategy is central to the scientific and ethical value of Bundibugyo vaccine development. A vaccine that demonstrates acceptable safety and immunogenicity during an outbreak must also be available in sufficient quantity, with release testing, cold-chain management, labeling, indemnification, import authorization, and field deployment protocols already planned. The Oxford/SII program illustrates a rapid manufacturing model in which investigational doses and a larger stockpile were produced before definitive efficacy data were available. The rVSV program illustrates a different challenge: strong platform precedent and animal evidence must be translated into GMP production, assay qualification, and clinical material availability. The mRNA program highlights the potential for rapid platform adaptation but requires a supply-chain and cold-chain plan suitable for affected districts.

Access strategy should be defined before efficacy results are available. Priority-use scenarios include ring vaccination around confirmed cases, vaccination of contacts and contacts of contacts, pre-exposure protection of frontline health workers and burial teams, and targeted vaccination in zones with sustained transmission. Funders and sponsors should define allocation principles, pricing, liability, data-sharing commitments,

pharmacovigilance obligations, and transition from emergency supply to a durable stockpile.

10. Regulatory Strategy

Regulatory strategy for Bundibugyo vaccines should be designed around emergency evidence generation, platform-based inference, and international alignment. A conventional placebo-controlled efficacy trial may be difficult if case numbers decline, if ring vaccination is ethically preferred, or if insecurity prevents consistent follow-up. Therefore, developers and regulators should pre-specify multiple evidence pathways: randomized ring-vaccination trials where feasible, individually randomized trials among contacts or high-risk workers, adaptive platform trials, immunogenicity studies with immune-bridging to nonhuman-primate protection, and emergency-use or compassionate-use mechanisms when benefits plausibly outweigh risks.

The most credible near-term regulatory approach will likely rely on a staged pathway. First, obtain national authorization and ethics approval for outbreak clinical trials in DRC and Uganda, with WHO coordination and independent data monitoring. Second, generate phase 1/2 safety and immunogenicity data as rapidly as possible, including harmonized assays for Bundibugyo glycoprotein binding and neutralizing antibodies. Third, collect efficacy data opportunistically during ring or targeted vaccination if transmission permits. Fourth, use platform comparability, animal-rule-like evidence where applicable, and immune-bridging to support emergency use listing, conditional authorization, or expanded access. Fifth, convert emergency evidence into a full licensure package through larger safety databases, manufacturing consistency data, pharmacovigilance, and post-authorization effectiveness studies.

Evidence component	Primary purpose	Key limitation
Phase I safety and immunogenicity	Establish initial tolerability, dose selection, and immune-response profile.	Does not demonstrate clinical protection.
Ring-vaccination or contact-based efficacy trial	Measures real-world protection in outbreak conditions.	Feasibility depends on incidence, security, contact tracing, and community acceptance.
Nonhuman-primate challenge studies	Provides controlled protection data and supports immune-bridging assumptions.	Requires careful model validation and translation to humans.
Immunobridging	Links human immune responses to protective thresholds inferred from animal or comparator data.	Requires credible immune correlates or surrogate endpoints.
Post-authorization effectiveness and safety studies	Confirms performance after emergency deployment and expands safety database.	Needs prospective data systems during a complex response.

Table 4. Evidence package for emergency authorization and eventual licensure of Bundibugyo vaccines.

11. Operational Considerations for Vaccine Trials

Outbreak vaccine trials must be operationally simple, ethically transparent, and integrated with response activities. Trial designs should prioritize high-risk contacts, contacts of contacts, frontline health workers, burial teams, laboratory staff, and communities with active transmission. Community engagement must precede enrollment, especially where distrust, misinformation, and insecurity are present. Cold-chain requirements, adverse-event monitoring, pregnancy considerations, pediatric inclusion, informed consent, and data capture must be planned before doses arrive. Importantly, vaccination should never replace surveillance, isolation, care, or infection prevention and control; it should reinforce them.

Figure 3. Clinical-trial decision framework




Figure 3. Clinical-trial decision framework. Trial design should adapt to transmission intensity, contact-tracing quality, security, and feasibility of follow-up while preserving independent monitoring and post-authorization evidence generation.

12. Strategic Implications for Filovirus Preparedness

The 2026 outbreak demonstrates that Ebola preparedness cannot be limited to Zaire ebolavirus. A resilient portfolio should include species-specific candidates for Bundibugyo, Sudan, and other pathogenic filoviruses; validated diagnostics; monoclonal antibody and antiviral options; regional manufacturing capacity; pre-approved clinical protocols; and standing community-engagement partnerships. The outbreak also supports a portfolio approach rather than reliance on a single platform. In the current portfolio, rVSV may be most mature for Ebola outbreak use, adenoviral vectors may provide robust scalability and complementary immunology, and mRNA may offer speed and antigenic flexibility. Coordinated investment is needed to move each from reactive emergency development to proactive readiness.

13. Conclusions

The Bundibugyo Ebola outbreak in DRC and Uganda is a severe public-health emergency and a test of global filovirus preparedness. The absence of a licensed Bundibugyo vaccine creates immediate operational risk but also a clear scientific agenda: rapidly evaluate the most promising candidates, protect communities through proven outbreak-control measures, and establish durable regulatory and manufacturing pathways before the next spillover. The most important vaccine-development priority is not merely to identify a promising candidate, but to build a complete system for evidence generation, authorization, deployment, monitoring, and community trust.

Organizations assessing Bundibugyo vaccine, diagnostic, immune-monitoring, or clinical-development programs can contact Lighthouse BioSolutions for an independent review of scientific strategy, assay readiness, evidence gaps, and regulatory options.

14. References

Editorial and medical disclaimer: *This publication is an independent scientific and strategic analysis prepared for professional informational purposes. It does not represent guidance from WHO, Africa CDC, a national regulatory authority, or a ministry of health, and it is not a substitute for current public-health, clinical, regulatory, legal, or biosafety guidance. Product-development status and outbreak figures should be verified against primary sources before decisions are made.*

1. World Health Organization. Ebola outbreak—DRC 2026: situation page and operational updates. 2026.
2. World Health Organization. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo and Uganda. Disease Outbreak News, 16 May 2026.
3. World Health Organization. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo and Uganda. Disease Outbreak News, 3 July 2026.
4. World Health Organization. Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus. 28 May 2026.

5. Centers for Disease Control and Prevention. Ebola outbreak: current situation. Updated 16 July 2026.
6. CDC. Notes from the Field: Outbreak of Ebola Disease Caused by Bundibugyo Virus—Democratic Republic of the Congo and Uganda, May 2026. MMWR. 2026.
7. European Centre for Disease Prevention and Control. Ebola disease outbreak in the Democratic Republic of the Congo and Uganda. Updated 17 July 2026.
8. European Centre for Disease Prevention and Control. Threat assessment brief: Ebola disease outbreak caused by Bundibugyo virus—Democratic Republic of the Congo and Uganda—2026. 21 May 2026.
9. Africa CDC. Bundibugyo Virus Disease Outbreak Situation Report, Issue No. 01. 18 May 2026.
10. Coalition for Epidemic Preparedness Innovations. CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates. 31 May/1 June 2026.
11. Gavi, the Vaccine Alliance. From market failure to epidemic preparedness: the race for a Bundibugyo Ebola vaccine. 5 June 2026.
12. Gavi, the Vaccine Alliance. Bundibugyo, the rare virus causing a deadly new Ebola outbreak, has no vaccine yet. 22 May 2026.
13. IAVI. IAVI to advance vaccine candidate for Bundibugyo virus, receives funding from CEPI. 1 June 2026.
14. IAVI. Bundibugyo virus vaccine programme overview. 2026.
15. University of Oxford. World's first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group. 13 July 2026.
16. Oxford Vaccine Group. BD-Ebov: developing a vaccine against Bundibugyo ebolavirus. 2026.
17. Reuters. Moderna and other groups get roughly US\$60 million to develop Ebola vaccine. 1 June 2026.
18. Reuters. Oxford begins first human trial of Bundibugyo Ebola vaccine. 13 July 2026.
19. The BMJ. Ebola: three vaccines rushed into development for Bundibugyo outbreak. 2026.
20. The BMJ. Ebola vaccine: Oxford starts UK trial against Bundibugyo strain. 2026.
21. The Lancet. Bundibugyo ebolavirus from the 2026 Ebola outbreak in Uganda and DR Congo: a new variant. 2026.
22. Wellcome. The 2026 Bundibugyo Ebola outbreak: why R&D investment matters. 2026.
23. Sabin Vaccine Institute. Sudan Ebolavirus Vaccine Development Program. 2026.

24. Sabin Vaccine Institute. Completion of enrollment in Phase 2 cAd3-Marburg and cAd3-Sudan Ebolavirus vaccine trials. 2026.
25. ClinicalTrials.gov. NCT06036602: Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults.
26. U.S. Food and Drug Administration. Animal Rule Information. 2024.
27. U.S. Food and Drug Administration. Animal Rule Approvals. 2024.
28. Finch CL, et al. Bridging Animal and Human Data in Pursuit of Vaccine Licensure. *Vaccines*. 2022;10(9):1384.
29. Wolfe DN, et al. Selection of Filovirus Isolates for Vaccine Development Programs. *Vaccines*. 2021;9(9):1045.
30. IAVI. New IAVI-authored paper proposes additional regulatory pathways for filovirus vaccines. 2023.